(HealthDay News) — Prostate-specific antigen (PSA) screening likely results in a reduction in prostate cancer-specific mortality, according to a review published online May 15 in the Cochrane Database ...
What we choose to call cancer may shape patients’ behavior in ways that influence their health outcomes. Relabeling low-grade ...
4don MSN
Novel prostate cancer treatment can reduce risk of disease progression by half, clinical trial shows
A Phase III clinical trial led by Neeraj Agarwal, MD, FASCO, senior director of clinical research at Huntsman Cancer ...
"ASCO26: Talzenna and Xtandi combo has first-line promise in HRR altered-mCSPC" was originally created and published by ...
To address these concerns, the research team developed a decision-analytical model to estimate how relabeling GG1 disease ...
A European study has demonstrated a sustained long-term reduction in prostate cancer mortality through prostate-specific antigen (PSA) screening. However, the findings also highlight the issue of ...
A dose reduction of Erleada may result in fewer skin-related side effects for men with advanced prostate cancer — but only for those with a smaller body size, research showed. A dose reduction of ...
Results of a multicenter clinical trial found that adding the investigational adenoviral-based viral immunotherapy ...
NHS advisors have again rejected pleas for potentially life-saving routine prostate cancer screening after concluding that ...
Observational data suggested that men with nonmetastatic prostate cancer lived longer if they followed a healthier lifestyle. A higher prostate cancer behavior score was associated with reductions in ...
Cancer. For many, this word brings an instant sense of negativity. Hearing the word cancer, whether in a personal context ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results